Patents Issued in November 9, 2017
  • Publication number: 20170319677
    Abstract: The present invention is related to various vaccine compositions against Bordetella avium and methods for preparing and administering the various vaccine compositions. The present invention is related to multivalent vaccines compositions such as bivalent or trivalent vaccines for inoculating turkeys against from Bordetella avium rhinotracheitis or coryza due to Bordetella avium infection as well as methods of preparing and administering the multivalent vaccine compositions.
    Type: Application
    Filed: May 3, 2017
    Publication date: November 9, 2017
    Inventors: Marcus M. JENSEN, Richard A. ROBISON
  • Publication number: 20170319678
    Abstract: This disclosure provides attenuated P. multocida strains which can be used to prepare vaccine compositions useful for protection against P. multocida.
    Type: Application
    Filed: May 5, 2016
    Publication date: November 9, 2017
    Inventors: Robert E. Briggs, Fred M. Tatum
  • Publication number: 20170319679
    Abstract: Provided herein are HIV-1 vaccines comprising a carrier and a population episensus antigen determined using the EpiGraph approach. Also provided are HIV-1 vaccines comprising a carrier, a population episensus antigen, and a tailored antigen. Also provided are methods of designing and producing an HIV-1 vaccine for a subject comprising designing vaccine antigens to optimally cover the diversity within a geographic area using an antigen amino acid sequence generated using the EpiGraph approach, and producing said designed vaccine antigen. Also provided are methods of inducing an effector memory T cell response comprising designing the one or more EpiGraph amino acid sequences, producing a vaccine comprising the one or more EpiGraph amino acid sequences and a vector, and administering the vaccine to a subject. Further provided are methods of treating HIV-1 in a subject comprising administering an effective amount of the described HIV-1 vaccines to the subject in need thereof.
    Type: Application
    Filed: October 5, 2015
    Publication date: November 9, 2017
    Applicant: Vir Biotechnology, Inc.
    Inventors: Eric E. BRUENING, Klaus FRUEH, Louis PICKER, Bette T. KORBER, James THEILER, Emily MARSHALL
  • Publication number: 20170319680
    Abstract: The present invention provides the induction of novel Th1 response, the induction of cytotoxic T cells and anti-cancer/anti-allergic activity techniques. Provided is a combination of a CpG oligonucleotide and an STING agonist. Also provided is a composition which contains an STING agonist, can be used as a type-I adjuvant, and is characterized in that the STING agonist is administered together with a CpG oligonucleotide. Further provided is an anti-cancer agent comprising a CpG oligonucleotide and is characterized in that the CpG oligonucleotide is administered together with an STING agonist. Still further provided is a composition which contains a CpG oligonucleotide and can be used for reducing or eliminating the IgE-inducing activity of an STING agonist.
    Type: Application
    Filed: March 20, 2015
    Publication date: November 9, 2017
    Applicant: National Institutes of Biomedical Innovation, Health and Nutrition
    Inventors: Ken Ishii, Etsushi Kuroda, Burcu Temizoz
  • Publication number: 20170319681
    Abstract: The present invention relates to a lentiviral vector-based Japanese encephalitis (JE) immunogenic composition. The present invention is directed to a recombinant lentiviral vector expressing the precursor of membrane (prM) and the envelope (E) protein, in particular glycoprotein of a Japanese encephalitis virus (JEV) or immunogenic fragments thereof. The present invention also provides cells expressing the lentiviral vector, uses and methods to prevent a JEV infection in a mammalian host, especially in a human or an animal host, in particular a pig or a piglet, preferably a domestic pig or a domestic piglet.
    Type: Application
    Filed: December 7, 2015
    Publication date: November 9, 2017
    Inventors: Pierre CHARNEAU, Philippe DESPRES, Melissanne DE WISPELAERE, Philippe SOUQUE, Marie-Pascale FRENKIEL
  • Publication number: 20170319682
    Abstract: The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection.
    Type: Application
    Filed: February 15, 2017
    Publication date: November 9, 2017
    Inventors: Gale SMITH, Yingyun WU, Michael MASSARE, Ye LIU
  • Publication number: 20170319683
    Abstract: Disclosed herein are methods of selecting an allogeneic T cell line for therapeutic administration to a patient having or suspected of having a pathogen or cancer. Also disclosed are methods of selecting a donor from whom to derive an allogeneic T cell line for therapeutic administration to a patient having or suspected of having a pathogen or cancer.
    Type: Application
    Filed: November 4, 2015
    Publication date: November 9, 2017
    Applicant: Memorial Sloan Kettering Cancer Center
    Inventors: Richard J. O'Reilly, Ekaterina Doubrovina, Guenther Koehne, Aisha N. Hasan, Susan E. Prockop
  • Publication number: 20170319684
    Abstract: The invention relates to novel artificial antigen presenting cells (aAPCs). The aAPC comprises at least one stimulatory ligand and at least one co-stimulatory ligand where the ligands each specifically bind with a cognate molecule on a T cell of interest, thereby mediating expansion of the T cell. The aAPC of the invention can further comprise additional molecules useful for expanding a T cell of interest. The aAPC of the invention can be used as an “off the shelf’ APC that can be readily designed to expand a T cell of interest. Also, the aAPC of the invention can be used identify the stimulatory, co-stimulatory, and any other factors that mediate growth and expansion of a T cell of interest. Thus, the present invention provides powerful tools for development of novel therapeutics where activation and expansion of a T cell can provide a benefit.
    Type: Application
    Filed: December 21, 2016
    Publication date: November 9, 2017
    Inventors: James L. Riley, Carl H. June, Robert H. Vonderheide, Nicole Aqui, Megan M. Davis
  • Publication number: 20170319685
    Abstract: The present invention is drawn to compositions and methods to enhance an immune response in order to prevent or treat infections or hyperproliferative diseases such as cancer. More particularly, the composition is an immunostimulatory intracellular signaling peptide fused directly or indirectly to a peptide that leads to multimerization into complexes of three or more units, where the intracellular signaling peptide must be present in a complex of three or more units in order to stimulate an immune response. Inserting this fusion construct into viruses like HIV-1 or introducing it into dendritic cells or tumor cells is predicted to lead to a positive therapeutic effect in humans, non-human mammals, birds, and fish.
    Type: Application
    Filed: March 16, 2017
    Publication date: November 9, 2017
    Inventors: Richard Syd Kornbluth, Geoffrey William Stone
  • Publication number: 20170319686
    Abstract: A vaccine for activating CD8 T cells including Bacillus Calmette-Guérin (BCG bacteria) which express a protein derived from a pathogenic microorganism as an active ingredient is beneficial because it can activate pathogenic microorganism-derived-antigen-specific CD8 T cells
    Type: Application
    Filed: November 17, 2015
    Publication date: November 9, 2017
    Inventors: Shihoko AIZAWA, Mitsuo HONDA, Satoshi HAYAKAWA
  • Publication number: 20170319687
    Abstract: The invention provides for a RANKL-specific antagonistic agent recognizing human platelet-expressed receptor activator of nuclear factor kappa-B ligand (pRANKL), for use in treating a cancer patient to prevent or reduce premetastatic lesions in blood.
    Type: Application
    Filed: November 12, 2015
    Publication date: November 9, 2017
    Applicant: Probiocon GmbH
    Inventors: Helmut SALIH, Ludger GROSSE-HOVEST, Andreas HERRMANN, Hans-Georg KOPP, Stefanie RAAB
  • Publication number: 20170319688
    Abstract: Provided herein are anti-RSPO3 antibodies and methods of using the same.
    Type: Application
    Filed: April 13, 2017
    Publication date: November 9, 2017
    Applicant: GENENTECH, INC.
    Inventor: Elaine Storm
  • Publication number: 20170319689
    Abstract: The invention relates to treating or preventing anaemia in a subject, such as a mammal or human. In particular, the invention addresses moderate to severe anaemia. Additionally, the invention provides means for sparing administration of erythropoiesis stimulating agents (ESAs) to subjects.
    Type: Application
    Filed: June 1, 2017
    Publication date: November 9, 2017
    Applicant: Kymab Limited
    Inventors: Volker GERMASCHEWSKI, Igor Theurl, Martin Yateman, Jasper Clube, Steve Arkinstall
  • Publication number: 20170319690
    Abstract: Anti-PD-L1 antibodies are disclosed. Also disclosed are pharmaceutical compositions comprising such antibodies, and uses and methods using the same.
    Type: Application
    Filed: June 15, 2017
    Publication date: November 9, 2017
    Inventors: Cheng-i Wang, Hsueh Ling Janice Oh, Siok Ping Yeo
  • Publication number: 20170319691
    Abstract: The invention provides compositions and methods for treating breast cancer. Specifically, the invention relates to administering a Transforming Growth Factor beta (TGF?) antagonist in combination with capecitabine and ixabepilone to treat breast cancer.
    Type: Application
    Filed: January 9, 2017
    Publication date: November 9, 2017
    Inventors: JAY HARPER, Scott LONNING, Frank HSU
  • Publication number: 20170319692
    Abstract: Provided herein are compositions, systems, kits, and methods for treating cancer in a subject with androgen receptor positive cancer cells by sensitizing such cancer cells with anti-androgen receptor therapy (e.g., Enzalutamide or anti-androgen antibody), and then treating with radiation therapy.
    Type: Application
    Filed: April 21, 2017
    Publication date: November 9, 2017
    Inventor: Mohamed Abazeed
  • Publication number: 20170319693
    Abstract: The present invention provides a technique for treating the cornea. More specifically, the present invention is an agent for the treatment or prevention of a state of corneal endothelial disease, the agent including at least one factor selected from the group consisting of laminin and fragments thereof, wherein the problem is solved by also providing a technique characterized in that this agent is administered together with corneal endothelial cells. Specifically, the present invention can include laminin 511 (?5?1?1), laminin 521 (?5?2?1), or a fragment of these.
    Type: Application
    Filed: October 30, 2015
    Publication date: November 9, 2017
    Applicants: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION, THE DOSHISHA, SENJU PHARMACEUTICAL CO., LTD.
    Inventors: Noriko KOIZUMI, Naoki OKUMURA, Shigeru KINOSHITA
  • Publication number: 20170319694
    Abstract: The present invention relates to new dihydoxyphenyl modulators of neurotransmitter levels, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Application
    Filed: July 21, 2017
    Publication date: November 9, 2017
    Inventors: David S. Goldstein, Courtney Holmes, Rudolf-Giesbert Alken, Frank Schneider, Chengzhi Zhang
  • Publication number: 20170319695
    Abstract: Described herein are neuroactive steroids of the Formula (I): or a pharmaceutically acceptable salt thereof; wherein , A, R1, R2, and R3 are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use, e.g., for treating a subject suffering from a disease or disorder described herein.
    Type: Application
    Filed: July 26, 2017
    Publication date: November 9, 2017
    Inventors: Albert J. Robichaud, Gabriel Martinez Botella, Francesco G. Salituro, Boyd L. Harrison
  • Publication number: 20170319696
    Abstract: Herein are provided derivatized hyperbranched polyglycerols (“dHPGs”). The dHPG comprises a core comprising a hyperbranched polyglycerol derivatized with C1C20 alkyl chains and a shell comprising at least one hydrophilic substituent bound to hydroxyl groups of the core, wherein the hyperbranched polyglycerol comprises from about 1 to about 200 moles of the at least one hydrophilic substituent. The dHPGs are for use as agents for the delivery of a drug or other biologically active moiety to the urinary tract, the digestive tract, the airways, the vaginal cavity and cervix and the peritoneal cavity to treat indications such as cancer, which may be useful in the treatment of or the manufacture of a medicament, in the preparation, of a pharmaceutical composition for the treatment of cancer, as a pre-treatment or co-treatment to improve drug uptake in a tissue. Furthermore, there are provided methods of making dHPGs.
    Type: Application
    Filed: December 22, 2016
    Publication date: November 9, 2017
    Inventors: Helen M. Burt, Donald E. Brooks, Jayachandran N. Kizhakkedathu, Richard Liggins, Dechi Guan, Lu Ye, Clement Mugabe, Alan So, Martin E. Gleave, John K. Jackson, Rajesh Kumar Kainthan
  • Publication number: 20170319697
    Abstract: A valerian composition includes a therapeutically effective pharmaceutical dosage form having a solid core including a polymer in which valerian and a valerian stability improving amount of an acidifying agent are contained. The valerian stability improving amount of acidifying agent being sufficient to impart a pH of 2 to 5 to the polymer.
    Type: Application
    Filed: May 4, 2017
    Publication date: November 9, 2017
    Applicant: Physician's Seal, LLC
    Inventors: Syed M. Shah, Christopher Diorio, Daniel Hassan, Fred Hassan
  • Publication number: 20170319698
    Abstract: The present invention provides a gastric retentive gel composition comprising: (a) a hydrophobic or amphiphilic liquid gelled with an organogelator; (b) an active agent; and (c) a hard wax or wax-like additive, for controlled delivery of the active agent to or through the upper gastrointestinal tract, in particular to or through the stomach. The gel composition forms a stable, floating and coherent raft in the gastric environment, and is not directly expelled from the stomach as a result of gastric emptying. The active agent is released from the composition in a controlled manner for absorption or local action.
    Type: Application
    Filed: October 26, 2015
    Publication date: November 9, 2017
    Inventors: Guy VERGNAULT, Ubaldo CONTE, Lauretta MAGGI
  • Publication number: 20170319699
    Abstract: Provided is a drug carrier for treatment of atherosclerosis including a biocompatible amphipathic polymer including a macrophage lignad polymer and a hydrophobic substance, and a hydrophobic drug.
    Type: Application
    Filed: November 8, 2016
    Publication date: November 9, 2017
    Inventors: Jin Won KIM, Hong Ki YOO, Kyeong Soon PARK
  • Publication number: 20170319700
    Abstract: The present invention provides implants comprising a therapeutic drug and a polymer containing polylactic acid (PLA) and optionally polyglycolic acid (PGA). The present invention also provides methods of maintaining a therapeutic level of a drug in a subject, releasing a therapeutic drug at a substantially linear rate, and treating schizophrenia and other diseases and disorders, utilizing implants of the present invention.
    Type: Application
    Filed: June 19, 2017
    Publication date: November 9, 2017
    Inventors: Steven Siegel, Karen WINEY
  • Publication number: 20170319701
    Abstract: The present invention provides implants comprising a therapeutic drug and a polymer containing polylactic acid (PLA) and optionally polyglycolic acid (PGA). The present invention also provides methods of maintaining a therapeutic level of a drug in a subject, releasing a therapeutic drug at a substantially linear rate, and treating schizophrenia and other diseases and disorders, utilizing implants of the present invention.
    Type: Application
    Filed: June 19, 2017
    Publication date: November 9, 2017
    Inventors: Steven Siegel, Karen Winey
  • Publication number: 20170319702
    Abstract: An injectable, nonaqueous suspension including at least one therapeutic agent suspended in a single component vehicle. The single component vehicle is a single amphiphilic material, such as a polyethoxylated castor oil or derivative thereof, a polyoxyethylene alkyl ether, a polyoxyethylene sorbitan fatty acid ester, a polyoxyethylene stearate, a block copolymer of polyethylene oxide-polypropylene oxide-polyethylene oxide, a block copolymer of polypropylene oxide-polyethylene oxide-polypropylene oxide, a tetra-functional block copolymer of polyethylene oxide-polypropylene oxide, or a tetra-functional block copolymer of polypropylene oxide-polyethylene oxide. A dosage kit that includes the injectable, nonaqueous suspension and a method of administering the injectable, nonaqueous suspension are also disclosed.
    Type: Application
    Filed: May 1, 2017
    Publication date: November 9, 2017
    Applicant: Durect Corporation
    Inventors: Paul R. Houston, Guohua Chen, Andrew Luk
  • Publication number: 20170319703
    Abstract: The disclosure provides dry, lipid-based mixtures comprising at least 50% by weight lipid molecules. The mixtures may comprise alkalizer molecules, non-hydrocolloidal emulsifiers and active ingredients, such as probiotic microorganisms, hyaluronan, and polyols (e.g. xylitol).
    Type: Application
    Filed: May 3, 2017
    Publication date: November 9, 2017
    Inventor: Jeffrey T. Haley
  • Publication number: 20170319704
    Abstract: Amphiphilic block copolymers (BCPs) were prepared comprising a poly(ethylene oxide) block and a biodegradable polycarbonate block functionalized with disulfide groups and carboxylic acid groups. The BCPs form self-assembled micellar particles in aqueous solution that can be loaded with hydrophobic drugs for therapeutic drug delivery. The loaded particles have small particle sizes (<100 nm), narrow particle size distributions, and high drug loading capacity (up to about 50 wt %) based on total dry weight of the loaded particles. Particles loaded with DOX released the DOX in response to changes in pH and glutathione (GSH) redox chemistry. The loaded particles efficiently delivered and released DOX within tumor cells, effectively suppressing growth of the tumor cells at a similar or even lower drug concentration than free DOX. Blank particles containing no DOX did not induce cytotoxicity to cells.
    Type: Application
    Filed: May 3, 2016
    Publication date: November 9, 2017
    Inventors: Willy Chin, Yukti Choudhury, Shujun Gao, James L. Hedrick, Xiyu Ke, Min-Han Tan, Jye Yng Teo, Yi Yan Yang
  • Publication number: 20170319705
    Abstract: Embodiments of the invention provide derivatives of Amphotericin B having increased solubility and reduced toxicity relative to AMB, while retaining antifungal activity against multiple clinical fungal isolates. Derivatives of AMB are provided comprising a polymer group having an amine group, the polymer linked to mycosamine via a relatively stable linker such as an amide linker. The derivatives may be of the general formula [I]: wherein R is H, C1-4 alkyl or phenyl; R2 is (CH2)m wherein m is between 0 and 4; R3 and R4 are each independently H or C1-4 alkyl, R5 is or OH, R6 is selected from a group consisting of: amide and alkyl, and R7 is a water-soluble polymer, and pharmaceutically acceptable salts, solvates, hydrates, diastereomers, and prodrugs of the compound of Formula [I].
    Type: Application
    Filed: July 24, 2017
    Publication date: November 9, 2017
    Inventors: Itai BENHAR, Nir OSHEROV, Vladimir DERGACHEV, Alex Martin SZPILMAN
  • Publication number: 20170319706
    Abstract: Provided is a method of delivering a drug to a mucosal surface in a living body, said method comprising applying a solution to said mucosal surface, wherein said solution comprises a cationic polymer dissolved in water, wherein said cationic polymer comprises a cationic functional group covalently attached to a polysaccharide polymer backbone selected from the group consisting of amylodextrin polymers, methylcellulose polymers, and hydroxypropyl methylcellulose polymers.
    Type: Application
    Filed: November 5, 2015
    Publication date: November 9, 2017
    Inventors: Jaime L. Curtis-Fisk, Robert B. Appell, Peter M. Margl, Susan L. Jordan, True L. Rogers
  • Publication number: 20170319707
    Abstract: The present invention relates to a composition and a combination comprising at least one first drug and at least one protein-binding prodrug, wherein the protein-binding prodrug comprises a protein-binding group, a second drug, and a linker that can be cleaved hydrolytically, enzymatically, or in a pH-dependent manner in the body, as well as to a kit and a pharmaceutical composition comprising said composition or combination.
    Type: Application
    Filed: July 14, 2017
    Publication date: November 9, 2017
    Inventor: Felix KRATZ
  • Publication number: 20170319708
    Abstract: The present disclosure provides derivatives of 3-substituted piperidine-2,6-diones, non-covalently bound complexes with serum albumin, pharmaceutical compositions of the same, and methods of use thereof. The non-covalently bound complexes are significantly more water-soluble than the parent compounds, and are useful for the treatment of a cancer, such as multiple myeloma.
    Type: Application
    Filed: October 22, 2015
    Publication date: November 9, 2017
    Inventor: Qun Sun
  • Publication number: 20170319709
    Abstract: A maytansinoid is covalently linked through a non-cleavable linker to an EGFR antibody that is a full EGFR antagonist, such as cetuximab or panitumumab. The result is an anti-cancer agent having cytotoxicity that is potentiated in cancer cells but not normal cells. This benefit is not seen with EGFR antibodies that are partial antagonists, or with toxins that are not processed by lysosomes.
    Type: Application
    Filed: July 4, 2014
    Publication date: November 9, 2017
    Inventor: Ilia Alexandre Tikhomirov
  • Publication number: 20170319710
    Abstract: Described herein are methods of making targeting peptides conjugated to a recombinant lysosomal enzyme by modifying the amino (N)-terminus and one or more lysine residues on a recombinant human lysosomal enzyme using a first crosslinking agent to give rise to a first crosslinking agent modified recombinant human lysosomal enzyme, modifying a lysine or cysteine within a short extension linker at the carboxyl (C)-terminus on a variant IGF-2 peptide having a short extension linker using a second crosslinking agent to give rise to a second crosslinking agent modified variant IGF-2 peptide, and then conjugating the first crosslinking agent modified recombinant human lysosomal enzyme to the second crosslinking agent modified variant IGF-2 peptide containing a short extension linker. Also described herein are conjugates synthesized using the methods disclosed herein. Also described herein are treatment methods using the disclosed conjugates.
    Type: Application
    Filed: November 9, 2016
    Publication date: November 9, 2017
    Applicant: AMICUS THERAPEUTICS, INC.
    Inventor: HUNG DO
  • Publication number: 20170319711
    Abstract: Disclosed are anti-5T4 antibody drug conjugates and methods for preparing and using the same.
    Type: Application
    Filed: May 23, 2016
    Publication date: November 9, 2017
    Applicant: WYETH LLC
    Inventors: Hans-Peter Gerber, John Francis DiJoseph, Kiran Manohar Khandke, Kimberly Ann Marquette, Puja Sapra, Lioudmila Gennadievna Tchistiakova
  • Publication number: 20170319712
    Abstract: Methods and compositions for enhancing the immune response to an IRM compound by depositing within a localized tissue region an IRM depot preparation that provides an extended residence time of active IRM within the localized tissue region.
    Type: Application
    Filed: July 27, 2017
    Publication date: November 9, 2017
    Applicant: 3M INNOVATIVE PROPERTIES COMPANY
    Inventors: RICHARD L. MILLER, MARK A. TOMAI, ROSS M. KEDL, ISIDRO ANGELO ELEAZAR ZARRAGA, RONNIE ORTIZ, JAMES D. STOESZ, PAUL D. WIGHTMAN
  • Publication number: 20170319713
    Abstract: An object of this invention is to provide a novel delivery means that enables efficient delivery of an active ingredient to a target cell. Such objective is attained by a lipoplex comprising dioleylphosphatidylethanolamine (DOPE), phosphatidylcholine, a cationic lipid, and an RNAi molecule and an industrial method for producing the same.
    Type: Application
    Filed: October 28, 2015
    Publication date: November 9, 2017
    Applicant: DELTA-FLY PHARMA, INC.
    Inventors: Tatsuhiro ISHIDA, Kiyoshi ESHIMA, Masakazu FUKUSHIMA
  • Publication number: 20170319714
    Abstract: One embodiment is directed to a system for altering the function of a sensory unit that innervates a targeted tissue region in an animal, the sensory unit being configured to express a light-responsive protein, comprising a light delivery element configured to direct radiation to at least a portion of a targeted tissue structure; and a light source configured to provide light to the light delivery element; wherein the targeted tissue structure is illuminated transcutaneously with radiation such that a membrane potential of cells comprising the targeted tissue structure is modulated at least in part due to exposure of the light-responsive protein to the radiation.
    Type: Application
    Filed: February 8, 2017
    Publication date: November 9, 2017
    Applicant: Circuit Therapeutics, Inc.
    Inventors: Christopher L. Towne, Dan Andersen
  • Publication number: 20170319715
    Abstract: One embodiment is directed to a method for altering the function of the sensory unit that innervates a targeted tissue region in a mammal comprising the steps of identifying the targeted tissue region; cutaneously administering into the targeted tissue region an adeno-associated virus wherein the viral genome encodes at least one exogenous protein; expressing the exogenous protein in the targeted sensory unit; and altering the function of the targeted sensory unit to treat or restore the sensory response because of the exogenous protein expression while not impacting the function of nearby sensory units.
    Type: Application
    Filed: February 8, 2017
    Publication date: November 9, 2017
    Applicant: Circuit Therapeutics, Inc.
    Inventors: Christopher L. Towne, Dan Andersen
  • Publication number: 20170319716
    Abstract: The present invention provides a tau protein aggregation inhibitor. In addition, a therapeutic agent or a preventive agent for tauopathy, including a tau protein aggregation inhibitor, and a method for screening for a tau protein aggregation inhibitor, are also provided. The problems are solved by a tau protein aggregation inhibitor including a fluorone dye or a pharmaceutically acceptable salt thereof. Moreover, the problems are also solved by a method for screening a tau protein aggregation inhibitor, wherein the method includes: (1) a step of preparing transgenic Drosophila that express a human tau protein in neurons, (2) a step of administering a candidate compound to the transgenic Drosophila, and (3) a step of measuring the motor function of the transgenic Drosophila that have been administered with the candidate compound in the step (2).
    Type: Application
    Filed: July 21, 2017
    Publication date: November 9, 2017
    Inventor: Yuji YOSHIIKE
  • Publication number: 20170319717
    Abstract: The present disclosure relates to prostate specific membrane antigen (PSMA) targeted compounds conjugated to near-infra red (NIR) dyes and methods for their therapeutic and diagnostic use. More specifically, this disclosure provides compounds and methods for diagnosing and treating diseases associated with cells and/or vasculature expressing prostate specific membrane antigen (PSMA), such as prostate cancer and related diseases. The disclosure further describes methods and compositions for making and using the compounds, methods incorporating the compounds, and kits incorporating the compounds.
    Type: Application
    Filed: June 15, 2017
    Publication date: November 9, 2017
    Inventors: Sumith A. Kularatne, Pravin Gagare
  • Publication number: 20170319718
    Abstract: Provided herein are methods and devices for identifying and/or distinguishing UCA formulations and specifically activating such formulations to produce UCA suitable for in vivo use.
    Type: Application
    Filed: May 4, 2017
    Publication date: November 9, 2017
    Applicant: Lantheus Medical Imaging, Inc.
    Inventors: Simon P. Robinson, Carol Walker, David C. Onthank, Joel Lazewatsky, Nhung Tuyet Nguyen
  • Publication number: 20170319719
    Abstract: There is provided herein a nanovesicle having a bilayer comprising a saturated first phospholipid and no more than about 15 molar % of a second phospholipid covalently conjugated to a J-aggregate forming dye.
    Type: Application
    Filed: July 27, 2017
    Publication date: November 9, 2017
    Applicant: UNIVERSITY HEALTH NETWORK
    Inventors: Gang Zheng, Elizabeth Huynh, Kenneth Ng, Mojdeh Shakiba, Robert Weersink, Brian Wilson
  • Publication number: 20170319720
    Abstract: A method for preparing a radiopharmaceutical and, specifically, a method for preparing an organic fluoride-aliphatic compound usable as a radiopharmaceutical, a method for purifying the prepared organic fluoride-aliphatic compound, and a method for preparing a radiopharmaceutical by using a cassette comprising a backdraft preventing reaction container. A method for preparing an organic fluorinated aliphatic compound includes allowing a fluorine salt to react with a leaving group-containing aliphatic compound by using a multifunctional solvent represented by the following Chemical Formula 1 to obtain an aliphatic compound labeled with [18F] fluoride substituting for the leaving group. The organic fluoride-aliphatic compound can be prepared and purified through even a simple process at high yield, high efficiency, and high purity, and the radiopharmaceutical can be safely prepared without damage to a synthetic apparatus.
    Type: Application
    Filed: November 6, 2015
    Publication date: November 9, 2017
    Inventors: Sang-ju LEE, Seung-jun OH, Dae-hyuk MOON, Jin-sook RYU, Jae-seung KIM, Jong-jin LEE
  • Publication number: 20170319721
    Abstract: The present invention provides a tissue-targeting complex comprising a tissue targeting moiety, an octadentate hydroxypyridinone-containing ligand and the ion of an alpha-emitting thorium radionuclide. The invention additionally provides therapeutic methods employing such complexes, methods of their production and use, and kits and pharmaceutical compositions comprising such complexes.
    Type: Application
    Filed: June 21, 2017
    Publication date: November 9, 2017
    Inventor: Thomas RAMDAHL
  • Publication number: 20170319722
    Abstract: The present application provides stable peptide-based CD8 capture agents and methods of use as detection agents. The application further provides methods of manufacturing CD8 capture agents.
    Type: Application
    Filed: April 4, 2017
    Publication date: November 9, 2017
    Inventors: Heather Dawn Agnew, Bert Tsunyin Lai
  • Publication number: 20170319723
    Abstract: Disclosed herein is a radioimmune complex comprising an epidermal growth factor receptor (EGFR)-targeted antibody and a radioactive isotope of rhenium labeled thereon. The EGFR-targeted antibody is cetuximab or panitumumab.
    Type: Application
    Filed: May 3, 2017
    Publication date: November 9, 2017
    Inventors: WAN-I KUO, KAI-HUNG CHENG, YI-SHU HUANG, SHENG-NAN LO, YA-JEN CHANG, TSUNG-TSE WU, WEI-CHUAN HSU, MING-HSIN LI, CHIH-HSIEN CHANG
  • Publication number: 20170319724
    Abstract: Systems and methods for sterilizing a column assembly including a column having an interior containing a retaining media and a parent radionuclide retained by the retaining media, an inlet port in fluid communication with the interior of the column, and an outlet port in fluid communication with the interior of the column. The method includes sealing at least one of the inlet port and the outlet port to form a sealed column assembly such that fluid communication with the column interior though both the inlet port and the outlet port is prevented, and sterilizing the sealed column assembly to form a terminally-sterilized column assembly.
    Type: Application
    Filed: January 20, 2017
    Publication date: November 9, 2017
    Inventors: Andrew D. Speth, Mark A. Spinelli, Sr., Gregory P. Wehmer, Bryan S. Petrofsky
  • Publication number: 20170319725
    Abstract: Apparatus and methods include a single-pair earphone sterilize with germicidal light. Embodiments include a housing and a germicidal light source. The apparatus may include circuitry, such as power, to support the germicidal light source and a divider to shield the circuitry from the germicidal light source. The apparatus may also include attachment portions to position and maintain earphones in a position relative to the germicidal light source.
    Type: Application
    Filed: February 21, 2017
    Publication date: November 9, 2017
    Inventor: Robert Hann
  • Publication number: 20170319726
    Abstract: Disclosed herein is a light source device using light-emitting diodes (LEDs). Specifically, a two-sided, surface light source device is implemented with point light sources such as LEDs in a simple configuration, such that even surface light is emitted. The two-sided, surface light source device includes: a substrate on which light-emitting diodes (LEDs) are disposed as a light source; and a two-sided diffusion unit having a plate-like shape with a front side face, a back side face, and a light-receiving face that is perpendicular to the front side face and the back side face and faces the substrate. Light emitted from the light source is diffused in the diffusion unit and exits through the front side face and the back side face.
    Type: Application
    Filed: November 4, 2015
    Publication date: November 9, 2017
    Inventor: Jae Jo KIM